Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 2/20 | 0.58 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.58 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.58 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.58 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.49 |
| ▸ | GJB2 | P29033 | 2/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18542463 | 1.00 | SSTR5 (0.58) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL8336531 | 1.00 | SSTR5 (0.58) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL3147529 | 1.00 | SSTR5 (0.58) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL4587088 | 1.00 | SSTR5 (0.58) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL8992036 | 1.00 | SSTR5 (0.58) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL12729388 | 1.00 | SSTR5 (0.58) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL13088352 | 1.00 | SSTR5 (0.58) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL13005380 | 1.00 | SSTR5 (0.58) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL3151671 | 0.96 | SSTR5 (0.57) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL22927969 | 0.94 | SSTR1 (0.62) | SSTR5SSTR1SSTR2SSTR4SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445652-B2 | 3, 6-O-bridged pyranose inversion compound and process for producing B-O-pyranoside | KWANSEI GAKUIN EDUCATIONAL FOUNDATION (JP) | 2013-05-21 | — | — | US | disclosed |
| US-20100324275-A1 | 3, 6-O-BRIDGED PYRANOSE INVERSION COMPOUND AND PROCESS FOR PRODUCING B-O-PYRANOSIDE | KWANSEI GAKUIN EDUCATIONAL FOUNDATION (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324275-A1 | 3, 6-O-BRIDGED PYRANOSE INVERSION COMPOUND AND PROCESS FOR PRODUCING B-O-PYRANOSIDE | CBR3, OXER1, CBR1 | SSTR5 3923/4885SSTR1 2128/4885SSTR2 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.